CIRUGÍA Y SUS ESPECIALIDADES
DEPARTAMENTO
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (2)
2024
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
-
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
European Journal of Cancer, Vol. 199